Plasma DPP4 activity is associated with no-reflow and major bleeding events in Chinese PCI-treated STEMI patients

Area of Science:

• Cardiovascular Medicine
• Biochemistry
• Clinical Research

Background:

• Dipeptidyl peptidase-4 (DPP4) plays a role in incretin regulation and inflammation, contributing to myocardial infarction (MI) pathophysiology.
• Understanding plasma DPP4 activity (DPP4a) in ST-segment elevation myocardial infarction (STEMI) patients post-percutaneous coronary intervention (PCI) is crucial for risk stratification.

Purpose of the Study:

• To investigate the association between plasma DPP4 activity (DPP4a) and clinical outcomes in STEMI patients treated with PCI.
• To determine the relationship between DPP4a levels and the incidence of no-reflow, major adverse cardiac or cerebrovascular events (iMACCE), in-hospital complications (IHC), and major bleeding.

Main Methods:

• A cohort of 747 consecutive STEMI patients undergoing PCI was recruited.
• Plasma DPP4 activity (DPP4a) was measured.
• Multivariate logistic regression analyses were performed to assess associations with outcomes, adjusting for confounding variables.

Main Results:

• DPP4a levels were lower in STEMI patients compared to controls.
• A 1 U/L increase in DPP4a was independently associated with a higher rate of no-reflow events (OR: 1.07; 95% CI: 1.02-1.11).
• Increased DPP4a was also associated with a lower rate of major bleeding events (OR: 0.90; 95% CI: 0.82-0.98); no association was found with iMACCE or IHC.

Conclusions:

• Elevated plasma DPP4 activity is an independent predictor of increased no-reflow events in PCI-treated STEMI patients.
• Higher DPP4a levels are associated with a reduced risk of major bleeding in this patient population.
• DPP4a may serve as a potential biomarker for predicting specific complications in STEMI patients undergoing PCI.